Lilly and Merck Lead the Way With Asian FIPNet Strategies

There's a new acronym to learn:FIPNet--for fully integrated pharmaceutical network. Nowhere is the strategy more apparent than in Asia, where Big Pharma hopes to tap into the increasingly high quality research available in India and China--countries that also should prove to be a major source of future customers. Merck and Eli Lilly are two companies leading the FIPNet charge.

Being a FIPCO—a fully integrated pharmaceutical company—is so last century. Increasingly, many pharmas are adopting strategies that rely heavily on collaborations with multiple partners where those allies bear a much greater proportion of the development risk in exchange for a greater share of the economic reward. In the twenty-first century parlance, it’s about FIPNets—fully integrated pharmaceutical networks.

Nowhere is the strategy more apparent than in Asia, where Big Pharma hopes to tap into the increasingly high quality...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Global Vision

More from In Vivo

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By 

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.

‘Confident In Lorundrostat’s Promise’: Mineralys CEO Talks Trials And Next Steps

 

In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.

BioBytes: Qubit Pharmaceuticals Unveils Quantum AI Model For Drug Discovery

 
• By 

Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.